Metabolic approaches to overcoming chemoresistance in ovarian cancer.
about
Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implicationIncreased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype.Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancerMetabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancerGlycolytic metabolism influences global chromatin structureROS Accumulation by PEITC Selectively Kills Ovarian Cancer Cells via UPR-Mediated ApoptosisEmerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cellsThe microenvironment reprograms circuits in tumor cellsChanging the energy of an immune responseMiR-338-3p targets pyruvate kinase M2 and affects cell proliferation and metabolism of ovarian cancer.Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells.Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis.Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia.Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer.Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer.Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer.Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancerOne-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer
P2860
Q26795759-E0AA754D-DFCC-44A2-A40C-390D9DF203F4Q33842748-7E6A0595-78FE-4135-BEBC-AFB2786EA26DQ34305438-AFBB80D1-1645-4ADC-A5F0-9F6010B0EEB9Q35046858-249C3049-C982-47B1-9478-6409EDFCAFCCQ35580164-79357C9F-F946-41DA-BC0F-1AF76F74A516Q35896411-079448F3-0FE3-4DDC-816F-72B9FE38BE8AQ36111593-59671DE2-BCFB-437D-BA78-12547A82A440Q36265840-4914BDEA-3254-4758-8DCE-2CAAEBAD7886Q36997790-7ECF2471-1F4F-4172-A199-61D83F834197Q37021691-05A53EE5-7106-4DDB-A78E-761F584DE4D1Q37144152-F96F0DE7-B676-4ECB-9333-A6E665A0630EQ37706871-3604387E-800F-48C3-AE40-A3784413EBEEQ37721603-4EF54CAA-D895-45AB-8F56-BD5673227C59Q38703674-F1189F16-5737-4806-92EF-420E486C73B2Q38761736-3F720F4D-4EED-4979-9DD1-97BA0E1E5C03Q38774498-9E7B7F25-8F78-489A-BAB7-1A0621350BA1Q38869922-396BC6E4-643B-4B21-BE5D-1B516E2D93D0Q38913984-3C72B765-2A80-451C-8072-E457843A1491Q41471256-B7E0E212-806F-426E-B907-82DA16B2EB10Q54414564-94200390-CEED-401A-80A1-FAC7D018C25BQ57817294-37627CEF-ED5F-4ACE-9BA0-D6F45596D238Q59134002-DBA34B19-AD4C-4531-A642-AADA7E2D7165
P2860
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
@en
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
@nl
type
label
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
@en
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
@nl
prefLabel
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
@en
Metabolic approaches to overcoming chemoresistance in ovarian cancer.
@nl
P2093
P2860
P1476
Metabolic approaches to overcoming chemoresistance in ovarian cancer
@en
P2093
Hyun Hoon Chung
Mi-Kyung Kim
Yong Sang Song
P2860
P356
10.1111/J.1749-6632.2011.06095.X
P407
P577
2011-07-01T00:00:00Z